Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Peptide Vaccine Doubles Clinical Response Rate in Advanced Melanoma

Patients with stage IV or locally advanced stage III cutaneous melanoma experienced higher response rates and longer progression-free survival (PFS) when treated with a gp100 vaccine and interleukin-2 than with interleukin-2 alone, in a phase 3 randomized trial. Tumors in all 185 patients expressed HLA*A0201, which allowed presentation of the peptide vaccine to T cells. The researchers concluded that their results show the potential of immune agents in combination with other treatments in this patient population.

 

Complete results are published in the June 2, 2011, edition of The New England Journal of Medicine (http://www.nejm.org/doi/full/10.1056/NEJMoa1012863).

Related Items
Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Patients with Advanced Cutaneous Squamous-Cell Carcinoma
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Skin Cancer
Lenalidomide Maintenance Therapy Benefits Patients With Multiple Myeloma
TOP - Daily published on May 15, 2012 in Skin Cancer
Can Aspirin Ward Off Melanoma?
TOP - Daily published on July 13, 2011 in Skin Cancer
Can Aspirin Ward Off Melanoma?
TON - Daily published on July 13, 2011 in Skin Cancer
Peptide Vaccine Doubles Clinical Response Rate in Advanced Melanoma
TON - Daily published on June 3, 2011 in Skin Cancer
Last modified: April 27, 2020